Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing treatments for serious diseases. Co.'s portfolio includes novel soluble guanylate cyclase (sGC) stimulators, namely praliciguat and olinciguat, as well as multiple research stage molecules. Praliciguat is a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. Olinciguat is a vascular sGC stimulator that the Co. intends to out-license for cardiovascular diseases. Co. operates through the human therapeutics segment. We show 26 historical shares outstanding datapoints in our CYCN shares outstanding history coverage, used to compute CYCN market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing CYCN market cap history over the course of time is important for investors
interested in comparing CYCN's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of CYCN versus a peer is one thing; comparing
CYCN market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like CYCN can fluctuate over the course of history.
With this page we aim to empower investors researching CYCN by allowing them to research the CYCN market cap history. |
Free CYCN Email Alerts:
Video: The Importance of Market Cap
